Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation.
Am J Trop Med Hyg
; 73(1): 166-70, 2005 Jul.
Article
em En
| MEDLINE
| ID: mdl-16014852
ABSTRACT
Malaria and anemia are common conditions in patients presenting to outpatient clinics in Kenya. Anemia is usually due to malaria infection with underlying micronutrient deficiency. Iron therapy has been shown to enhance recovery from anemia in children with malaria, without affecting malaria treatment. Iron and folic acid are often prescribed together for anemic individuals. Until recently in Kenya, the drug of first choice for non-severe malaria was sulfadoxine-pyrimethamine (SP), an antifolate antimalarial drug. In this study, 303 patients of all ages with anemia and uncomplicated Plasmodium falciparum malaria attending an outpatient clinic in an area of seasonal malaria were treated with SP and iron, and were randomized to receive folic acid. Parasite clearance rates were measured using a survival analysis plot for both parasitologic and clinical failure. There was a significant reduction in the efficacy of SP in patients taking standard therapeutic doses of folic acid using the survival curve for parasitologic failure (P < 0.0001), but no difference for clinical failure (P = 0.7008). Folic acid supplementation did not enhance recovery from anemia.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Malária Falciparum
/
Suplementos Nutricionais
/
Ácido Fólico
/
Malária
/
Antimaláricos
Tipo de estudo:
Clinical_trials
/
Etiology_studies
Limite:
Animals
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Am J Trop Med Hyg
Ano de publicação:
2005
Tipo de documento:
Article
País de afiliação:
Quênia